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Background: The importance of personalized medicine is becoming
increasingly recognized in anesthesia. Titration of the different drugs
used in anesthesiology has become possible due to monitors that allow
us to measure the different effects. However, regarding the analgesic
effect, there are not many available solutions yet. The Pupillary Reflex
Dilation has been studied as a surrogate for measuring the nociception/
antinociception balance of patients, both in the operating theater as
well as in intensive care.1 The aim of this study was to assess the
Pupillary Pain Index (PPI) association with different concentrations of
remifentanil.
Methods: This was an observational prospective study, where 34 con-
secutive patients were enrolled. Patients scheduled for neurosurgical
procedures, with general TIVA anesthesia with propofol and remifentanil
were considered when no premedication was used. Induction began with
an infusion of remifentanil targeted for a constant concentration using
Minto PK Model and then an infusion of propofol at 200mL/h was
started until loss of consciousness was observed. Afterwards, an infrared
portable pupillometer (AlgiScan—IDMed, France) was used to assess the
Pupillary Dilation Reflex and its derived index PPI. Following this
measurement, remifentanil concentrations could be increased or de-
creased if deemed necessary by the anesthesiologist. The PPI consists in
measuring the pupillary dilation in response to a continuously increasing
electric stimulus discharge, that stops when > 13% dilation from baseline
is achieved, or when 60mA is reached. PPI measurements were taken
after loss of consciousness and before surgery, at moments when no other
stimulus were present. For each measure of PPI the predicted effect-site
concentration (EC) of remifentanil (Minto PK model) and of propofol
(Schnider PK Model); and the BIS value were noted. Data are mean±
SD or %.
Results: A total of 78 measures of PPI were done. Patients’ data were:
57± 15 years; 73± 21 kg; 162±8 cm; 60% female; 11.5% ASA I; 80.8%
ASA II; Remifentanil EC 2.4± 1.5 ng/mL; propofol EC 3.7± 1.3 ug/mL;
BIS 46.1± 8.2; PPI 4.8 ± 3. A correlation was observed between the re-
mifentanil EC and PPI (R=−0.46, P< 0.001), but not between PPI and
propofol EC or BIS. A correlation was observed between BIS and pro-
pofol CE (R=−0.26, P= 0.028), but not with remifentanil. Tukey HSD
test showed that the different is mainly due to concentrations <3 versus
≥ 3 ng/mL.
Conclusions: We found a significant correlation between the remifentanil
concentration and PPI, showing that PPI discriminates different levels of
analgesia. No correlation was found with propofol or BIS. However,
there was no clear discrimination between all levels of remifentanil con-
centrations analyzed. Further research should be done, with more data
and more stratified levels of remifentanil.
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Background: Although there has been significant focus on unconsciousness
and amnesia, identifying the neural signatures of effective analgesia has re-
ceived less attention.1 Currently, appraisal of intraoperative nociception is
mostly done through the assessment of the autonomic response to noxious
stimuli, whether it is through heart rate variability, heartbeat intervals, ple-
thysmographic pulse wave amplitude, skin conductance or pupillary re-
sponse.2 The known wide inter-patient variability of the hypnotic effect,
namely in the amount of propofol needed to achieve loss of consciousness, led
us to question if this variability also happened for the analgesic effect. In this
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study, we evaluated the interpatient variability of the Pupillary Dilation Reflex
(PDR) response to different levels of remifentanil, administered using target
controlled infusion with the Minto Pk Model.
Methods: This is an observational prospective study, where 34 consecutive
patients were enrolled. Patients scheduled for neurosurgical procedures, with
TIVA (using target controlled infusion systems) with propofol and re-
mifentanil were considered when no premedication was used. Induction began
with a constant remifentanil concentration using Minto PK Model and then
an infusion of propofol at 200mL/h was started until loss of consciousness
was observed. Afterwards, an infrared portable pupillometer (AlgiScan—
IDMed, France) was used to assess the Pupillary Dilation Reflex and its
derived index Pupillary Pain Index (PPI). Remifentanil concentrations could
be increased if deemed necessary by the anesthesiologist. The PPI is calculated
from the PDR to a continuously increasing electric stimulus discharge. PPI
measurements were taken after loss of consciousness and before surgery, at
moments when no other stimulus were present. For each measure of PPI the
predicted effect-site concentration (EC) of remifentanil and of propofol
(Schnider PK Model); Data are mean±SD or %.
Results: Thirty-four consecutive patients were enrolled, and a total of
78 measures of PPI were done. Figure 1 shows the PPI variability for
different levels of remifentanil EC and Table 1 shows the PPI values for
the four levels of remifentanil. The variability found ranged from 80% to
500%, depending on the effect site concentration of remifentanil. The
higher the concentration, the larger the variability. The mean PPI is the
difference between the different Remifentanil EC levels (ANOVA
P< 0.001).
Conclusions: The variability of the analgesic effect was as high as 500%.
This suggests that more attention should be paid to the individualization
of intraoperative analgesia, as different patients have different analgesic
needs, and these need cannot be predicted only through PK-PD models.
Further research should be done, with more data and more stratified
levels of remifentanil.
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Background: Nitrous oxide (N2O), a unique anaesthetic agent, has both
advantages and disadvantages, especially in neurosurgical patients.
Various studies evaluating the use of N2O in different surgical pop-
ulations have been inconclusive so far.
Objectives: To compare duration of ICU and hospital stay in patients
receiving sevoflurane based general anesthesia with/without N2O, for elec-
tive cerebellopontine angle (CPA) tumor excision surgery. Secondarily, we
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